Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Anosys General Information
Anosys developed an exosome-based immunotherapy platform targeting cancer. Their lead program used autologous dexosomes to stimulate immune responses against tumor antigens in patients with advanced cancers such as melanoma and NSCLC. Early-phase trials showed promising safety and some efficacy signals, but the most recent clinical trial for Stage IV melanoma was suspended and there are no active programs as of mid-2025.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Santa Monica / general California presence, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Licensed core IP from INSERM France, Gustave-Roussy Institute France, Curie Institute France
Anosys Funding
No funding data available
To view Anosys's complete valuation and funding history, request access »